[go: up one dir, main page]

MX2017000059A - Metodos de tratamiento profilactico antivirales y kits de profilaxis previa a la exposicion. - Google Patents

Metodos de tratamiento profilactico antivirales y kits de profilaxis previa a la exposicion.

Info

Publication number
MX2017000059A
MX2017000059A MX2017000059A MX2017000059A MX2017000059A MX 2017000059 A MX2017000059 A MX 2017000059A MX 2017000059 A MX2017000059 A MX 2017000059A MX 2017000059 A MX2017000059 A MX 2017000059A MX 2017000059 A MX2017000059 A MX 2017000059A
Authority
MX
Mexico
Prior art keywords
hsv
methods
hiv
profilactic
profilaxis
Prior art date
Application number
MX2017000059A
Other languages
English (en)
Other versions
MX392650B (es
Inventor
RAMIREZ Christina
A Checcone Emidio
Original Assignee
Prophylaxis LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prophylaxis LLC filed Critical Prophylaxis LLC
Publication of MX2017000059A publication Critical patent/MX2017000059A/es
Publication of MX392650B publication Critical patent/MX392650B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente divulgación proporciona composiciones y métodos para la prevención de la infección por VHS en un individuo seronegativo respecto a VHS. El virus del herpes simple (VHS) se asocia en muchos individuos infectados con recidivas que se manifiestan como herpes labiales y/o herpes genitales, siendo ambos a menudo dolorosos y embarazosos. El VHS tiene también una trascendencia sanitaria significativa ya que la infección por VHS incrementa en un factor de 2-3 el riesgo de que una persona adquiera el virus de la inmunodeficiencia humana (VIH) e incremente el riesgo en un factor de 8 si la persona se expone a VIH poco después de adquirir el VHS. Por lo tanto, con el fin de abordarla epidemia por VIH también es necesario abordar la epidemia por VHS.
MX2017000059A 2014-07-07 2015-07-07 Metodos de tratamiento profilactico antivirales y kits de profilaxis previa a la exposicion MX392650B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462021589P 2014-07-07 2014-07-07
PCT/US2015/039421 WO2016007538A1 (en) 2014-07-07 2015-07-07 Viral prophylaxis treatment methods and pre-exposure prophylaxis kits

Publications (2)

Publication Number Publication Date
MX2017000059A true MX2017000059A (es) 2017-11-08
MX392650B MX392650B (es) 2025-03-24

Family

ID=55016233

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017000059A MX392650B (es) 2014-07-07 2015-07-07 Metodos de tratamiento profilactico antivirales y kits de profilaxis previa a la exposicion

Country Status (14)

Country Link
US (1) US10052329B2 (es)
EP (2) EP3166680B1 (es)
JP (3) JP7525976B2 (es)
KR (2) KR20240110074A (es)
CN (2) CN114469958A (es)
AU (3) AU2015287994B2 (es)
BR (1) BR112017000285A2 (es)
CA (1) CA2954526C (es)
ES (1) ES2964529T3 (es)
IL (2) IL273932B2 (es)
MX (1) MX392650B (es)
PL (1) PL3166680T3 (es)
SG (2) SG11201700061PA (es)
WO (1) WO2016007538A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11071745B2 (en) 2014-07-07 2021-07-27 Elian Llc Viral prophylaxis treatment methods and pre-exposure prophylaxis kits
CA2954526C (en) 2014-07-07 2023-03-07 Prophylaxis, Llc Viral prophylaxis treatment methods and pre-exposure prophylaxis kits
JP7019727B2 (ja) * 2017-02-08 2022-02-15 バイオトロン リミティッド インフルエンザの治療方法
PH12019502878B1 (en) * 2017-06-28 2024-02-21 Aicuris Gmbh & Co Kg Intravaginally applicable devices comprising antiviral compounds
WO2020077119A1 (en) * 2018-10-11 2020-04-16 Trustees Of Dartmouth College Compositions and methods for preventing or ameliorating neonatal hsv infection
MX2021004553A (es) * 2018-10-23 2021-07-16 Eastern Virginia Medical School Composiciones farmaceuticas y metodos para fabricar formulaciones de dosificacion solidas bajo demanda.
WO2020092990A1 (en) * 2018-11-02 2020-05-07 Eastern Virginia Medical School Pharmaceutical compositions and methods of making a patch formulation for transdermal delivery
MX2021010063A (es) 2019-02-25 2021-11-12 Elian Llc Tratamiento del herpes simplex con una combinación de valaciclovir y famciclovir.
CA3141337A1 (en) * 2019-05-24 2020-12-03 Piedmont Animal Health Inc. Long-acting injectable formulations and use thereof
BR112022008004A2 (pt) * 2019-10-29 2022-07-12 Tranexamic Tech Llc Composição, método e kit para intensificar a eficácia de um agente farmacêutico
US20210322469A1 (en) * 2020-04-20 2021-10-21 Regents Of The University Of Minnesota Zinc and copper for the prophylaxis and treatment of covid-19
BR112022021834A2 (pt) * 2020-05-05 2022-12-13 Merck Sharp & Dohme Llc Sistema de fornecimento de fármaco por implante, e, método para tratar ou prevenir infecção pelo vírus da imunodeficiência humana e prevenir gravidez

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795721A (en) 1990-06-11 1998-08-18 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of ICP4
EP1769821A1 (en) * 1998-04-21 2007-04-04 INFECTIO RECHERCHE Inc. Applicator for the delivery of topical formulations into mucosal cavities
GB9819898D0 (en) 1998-09-11 1998-11-04 Smithkline Beecham Plc New vaccine and method of use
DOP2000000109A (es) * 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
US20020091097A1 (en) 2000-09-07 2002-07-11 Bratzler Robert L. Nucleic acids for the prevention and treatment of sexually transmitted diseases
ES2558875T3 (es) 2006-03-22 2016-02-09 Starpharma Pty Limited Composición anticonceptiva
WO2009142827A2 (en) 2008-03-28 2009-11-26 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds and methods for the treatment of viral infection
US8853223B2 (en) * 2010-09-17 2014-10-07 G2L Touch, Inc. Therapeutic composition to treat lesions caused by herpes simplex virus
BR112012031497A2 (pt) * 2010-06-11 2016-11-01 Ayesha Kharsany formulações antivirais tópicas para a prevenção de transmissão de hsv-2
US9155873B2 (en) * 2011-05-17 2015-10-13 Reprotect, Inc. Reusable intravaginal delivery device, system, and method
CN103796708A (zh) * 2011-07-20 2014-05-14 帕特里克.F.凯瑟 用于递送药物的阴道内装置
ES2673556T3 (es) * 2012-05-16 2018-06-22 Immune Design Corp. Vacunas para el VHS-2
CA2954526C (en) 2014-07-07 2023-03-07 Prophylaxis, Llc Viral prophylaxis treatment methods and pre-exposure prophylaxis kits

Also Published As

Publication number Publication date
AU2020203896A1 (en) 2020-07-02
AU2022275517A1 (en) 2023-01-05
US10052329B2 (en) 2018-08-21
IL249938B (en) 2020-04-30
JP2021138723A (ja) 2021-09-16
CA2954526C (en) 2023-03-07
JP2017527610A (ja) 2017-09-21
IL273932A (en) 2020-05-31
EP3166680A4 (en) 2018-01-17
WO2016007538A1 (en) 2016-01-14
AU2020203896B2 (en) 2022-08-25
CN106794336A (zh) 2017-05-31
CN106794336B (zh) 2022-01-11
JP2023179575A (ja) 2023-12-19
NZ765819A (en) 2024-08-30
IL273932B2 (en) 2023-07-01
EP4342545A3 (en) 2024-06-26
ES2964529T3 (es) 2024-04-08
NZ728045A (en) 2024-08-30
EP3166680C0 (en) 2023-11-15
KR20170063512A (ko) 2017-06-08
KR20240110074A (ko) 2024-07-12
BR112017000285A2 (pt) 2017-10-31
CA2954526A1 (en) 2016-01-14
PL3166680T3 (pl) 2024-03-25
AU2015287994B2 (en) 2020-03-12
MX392650B (es) 2025-03-24
EP3166680B1 (en) 2023-11-15
EP3166680A1 (en) 2017-05-17
JP7525976B2 (ja) 2024-07-31
CN114469958A (zh) 2022-05-13
EP4342545A2 (en) 2024-03-27
SG11201700061PA (en) 2017-02-27
IL273932B1 (en) 2023-03-01
IL249938A0 (en) 2017-03-30
US20160000797A1 (en) 2016-01-07
AU2015287994A1 (en) 2017-02-02
SG10201913641XA (en) 2020-03-30

Similar Documents

Publication Publication Date Title
MX2017000059A (es) Metodos de tratamiento profilactico antivirales y kits de profilaxis previa a la exposicion.
MX369307B (es) Compuestos terapeuticos utiles para tratamiento profilactico o terapeutico de infeccion por virus de inmunodeficiencia humana.
MX358099B (es) Anticuerpos que neutralizan el virus de inmunodeficiencia humano y metodos de uso de ellos.
AR130699A2 (es) Inhibidores de la transcriptasa inversa de nucleósidos sustituidos en 4’
CO2017007619A2 (es) Anticuerpos humanos contra glicoproteína del virus ébola
CL2017001191A1 (es) Compuestos derivados de carbamoilpiridona policíclicos; composición farmacéutica que los comprende; y su uso para el tratamiento de una infección de vih en un humano que tiene o se encuentra en riesgo de tener la infección.
CR11310A (es) Espiro-Pirrolidinas y su uso contra infeccion por el virus de Hepatitis C (HCV) y por el virus de Inmunodeficiencia Humana (VIH)
MX2017008720A (es) Derivados y metodos para tratamiento de las infecciones por hepatitis b.
ECSP19020740A (es) Anticuerpos anti-cd27
MX2018012094A (es) Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas.
MX386403B (es) Anticuerpos humanos para hemaglutinina de influenza.
MX2017010506A (es) Nuevo derivado de quinoleina para usarse en el tratamiento y prevencion de infecciones virales.
CU20150096A7 (es) Compuestos de amida y composición farmacéutica para el tratamiento de vih
PH12017500393A1 (en) Pyrrolopyrimidines for use in influenza virus infection
ECSP12012106A (es) Terapia antiviral
MX370191B (es) Composiciones y su uso en el tratamiento de la inmunodeficiencia.
CL2016002276A1 (es) Composiciones tópicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad
CU24519B1 (es) Derivados de aminotiazol útiles como agentes antivíricos
CL2017000714A1 (es) Composiciones farmacéuticas de acción prolongada
BR112016022722A2 (pt) pró-fármacos de inibidores da transcriptase reversa de hiv
MX2021010063A (es) Tratamiento del herpes simplex con una combinación de valaciclovir y famciclovir.
CL2015003752A1 (es) Inhibidores de replicación viral, su proceso de preparación y sus uso terapeutico
MX2016002903A (es) Composiciones inmunogenas de la glicoproteina g de los virus hendra y nipah.
CL2017000884A1 (es) Composición farmacéutica para usarse en el tratamiento o la prevención de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugía de derivación gástrica
MX2020000694A (es) Composiciones que comprenden darunavir, cobicistat, emtricitabine y alafenamida de tenofovir para usar en el tratamiento del vih.